Novo Nordisk Juggles Pipeline Advances and Generic Threat as Share Buyback Hits $3.44 Billion

Novo Nordisk launches Phase 3 knee OA trial, gains FDA fast-track for heart drug, as first Ozempic generic approved in Canada. Stock remains 40% below year-ago levels.

Novo Nordisk is navigating a pivotal moment. The Danish drugmaker has been buying back its own shares at a steady clip, launching a new Phase 3 trial for knee osteoarthritis, and securing a coveted FDA fast-track designation — all while the first generic copy of its blockbuster Ozempic has been approved in Canada. The stock, trading at around €34.29, remains roughly 40% below its level from a year ago.

A Busy Week for the Pipeline

The company has kicked off a Phase 3 study dubbed AMAZE 5, testing its experimental drug NNC0487-0111 in overweight patients with knee osteoarthritis. The once-weekly injection aims to both reduce weight and alleviate pain, and recruitment is now underway. This marks a deliberate push into orthopedics, a new therapeutic area for the Danish group.

Separately, the US Food and Drug Administration granted fast-track status to Coramitug, a drug being evaluated in the ongoing CLEOPATTRA Phase 3 trial for ATTR amyloidosis with cardiomyopathy — a rare and serious heart condition. The designation accelerates the regulatory review process.

On the pediatric front, positive data from the PIONEER TEENS study showed that oral semaglutide achieved a statistically significant reduction in blood sugar in children and adolescents aged 10 to 17 with type 2 diabetes. Novo Nordisk plans to file for a label expansion in the US and EU in the second half of 2026.

Canada Opens the Door to Generics

The most significant competitive development came from Health Canada, which approved the first generic version of Ozempic (semaglutide), manufactured by Dr. Reddy's Laboratories. Another eight generic applications are under review by the Canadian regulator.

Canada is widely seen as a bellwether for other markets. If price erosion for GLP-1 drugs takes hold there, it could eventually ripple into the United States — Novo Nordisk's most lucrative market. The ultimate impact will depend on how quickly and broadly additional generics are approved.

Buyback Program Accelerates

Since launching its share repurchase program on February 4, 2026, Novo Nordisk has bought back roughly 13.4 million B-shares for 3.44 billion Danish kroner. The total program is set at 15 billion kroner over 12 months. The current tranche, capped at 3.8 billion kroner, runs until May 4. The average buyback price has been 256.48 kroner per share.

The stock recently changed hands at €34.15, down about 2.9% from the previous day but still more than 10% above its level a month ago. It has recovered from a 52-week low of €30.48 in March, and the relative strength index of 25.7 suggests oversold conditions. However, the share price remains roughly 19% below its 200-day moving average, indicating that the long-term upward momentum has yet to return.

Rival Stumbles Offer a Brief Reprieve

One factor supporting the recent recovery is a weaker-than-expected launch from Eli Lilly's new oral GLP-1 drug Foundayo. Prescription data from the US shows a sluggish start, which temporarily reduces competitive pressure on Novo Nordisk's core products Wegovy and Ozempic.

Despite this, analysts remain cautious. Kepler Capital maintains a "Hold" rating, noting that while the operational story is improving, the full-year guidance remains a drag. Novo Nordisk expects adjusted revenue growth of between minus 5% and minus 13% for 2026 on a constant-currency basis. The headwinds are multiple: Medicare Part D price negotiations, reduced Medicaid reimbursement for obesity treatments, and the "Most Favored Nations" pricing agreement are all squeezing margins.

First-Quarter Results Loom

Free cash flow for 2026 is forecast at 35 to 45 billion kroner, while capital expenditure is expected to reach around 55 billion kroner — a level that should decline in subsequent years as current projects are completed.

Novo Nordisk will report first-quarter results on May 6, 2026, before the market opens. It will be the first official data point under the negative annual guidance. Investors will be watching closely to see if management narrows the wide forecast range, and for updates on Wegovy prescription trends and pipeline developments — including Etavopivat, a sickle cell disease drug for which the company plans to seek its first approval in the second half of 2026.

The question hanging over the stock is whether pipeline expansion into cardiology, orthopedics, and pediatrics can offset the emerging generic threat from Canada — and whether the buyback program can provide enough support until the answer becomes clearer.